CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
CLM94 是一种具有抗 VEGFR-2 和抗血管生成特性的新型环酰胺，在体外和体内均能有效对抗原发性未分化甲状腺癌
期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5
doi:10.1210/jc.2011-1987
Alessandro Antonelli, Guido Bocci, Concettina La Motta, Silvia Martina Ferrari, Poupak Fallahi, Ilaria Ruffilli, Andrea Di Domenicantonio, Anna Fioravanti, Stefania Sartini, Michele Minuto, Simona Piaggi, Alessandro Corti, Greta Alì, Teresa Di Desidero, Piero Berti, Gabriella Fontanini, Romano Danes
